Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineAnetumab Ravtansine Shows Encouraging Activity in Multiple Solid Tumor Types

In this Journal of Clinical Oncology study, anetumab ravtansine yielded manageable safety, tolerability, pharmacokinetics, and clinical activity in a study of 148 heavily pretreated patients with mesothelin-expressing solid tumors.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form